NCT06422793 The Impact of Nasogastric Tube Gastric Decompression on Postoperative Nausea and Vomiting in Orthognathic Surgery
| NCT ID | NCT06422793 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nova Scotia Health Authority |
| Condition | Postoperative Nausea |
| Study Type | INTERVENTIONAL |
| Enrollment | 92 participants |
| Start Date | 2024-12-04 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 92 participants in total. It began in 2024-12-04 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will compare the incidence of postoperative nausea and vomiting during the first 24 hours following corrective jaw surgery (orthognathic surgery) in patients with and without nasogastric tube gastric decompression.
Eligibility Criteria
Inclusion Criteria: * Patients over the age of 16 at the time of consent undergoing orthognathic surgery for the correction of dentofacial deformities at the Victoria General Hospital during the study period. Orthognathic surgery to include: 1. Patients who receive single-jaw surgery (i.e. BSSO \[Bilateral Sagittal Split Osteotomy\] only, or LeFort only). 2. Patients receiving double-jaw surgery (i.e. BSSO and LeFort). 3. Patients undergoing a functional genioplasty in addition to another osteotomy (i.e. BSSO and/or LeFort). Exclusion Criteria: * Patients will be excluded if they do not meet inclusion criteria or if they have risk factors known to directly impact PONV and/or cause delayed gastric emptying: 1. Patients under the age of 16 at the time of consent. 2. Patients contraindicated to undergo elective surgery, including pregnant patients. 3. Patients undergoing a functional genioplasty procedure only. 4. Patients taking GLP-1 receptor agonists). 5. Patients with known gastroparesis.
Contact & Investigator
James Brady, DDS/MD
PRINCIPAL INVESTIGATOR
NSHA
Frequently Asked Questions
Who can join the NCT06422793 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Postoperative Nausea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06422793 currently recruiting?
Yes, NCT06422793 is actively recruiting participants. Contact the research team at katherinea.curry@nshealth.ca for enrollment information.
Where is the NCT06422793 trial being conducted?
This trial is being conducted at Halifax, Canada.
Who is sponsoring the NCT06422793 clinical trial?
NCT06422793 is sponsored by Nova Scotia Health Authority. The principal investigator is James Brady, DDS/MD at NSHA. The trial plans to enroll 92 participants.